Attorneys representing a class of buyers over the cholesterol medication Lipitor are currently in disagreement over the division of attorney fees in an antitrust litigation against Pfizer. The anticipated fees figure up to $31 million, a decision to be made by a New Jersey federal judge, but disputes about its division have sprung up prior to the total approval, as evidenced by available court documents.
The litigation implicates Lipitor, which is one of the pharmaceutical industry’s best-selling drugs, in an antitrust violation sparking a wide-reaching legal debate. The division of fees issue adds an additional layer of complication to an already complex legal battle.
Such fee disputes aren’t unusual in high-stakes class action suits, often invoking debate among different firms over the share of the fee pool. How this dispute resolves could set a precedent for similar cases in the future.
We will be closely monitoring the development of this case and provide timely updates to legal professionals.